Compare Amgen, Inc. (AMGN) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs D Wave Quantum Inc — how do they compare? Amgen, Inc. trades at $358.69 (market cap $196.12B), while D Wave Quantum Inc trades at $18.85 (market cap $7.44B). The key difference: Amgen, Inc. is far larger — about 26.4× D Wave Quantum Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while D Wave Quantum Inc pays none. Which is the better fit depends on your goals.
| AMGN | QBTS | |
|---|---|---|
Market Cap | $196.12B | $7.44B |
Sector | Health | Technology |
52-Week High | $388.16 | $44.78 |
52-Week Low | $271.18 | $12.98 |
Enterprise Value | $241.41B | $6.90B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
D-Wave Quantum (QBTS) trades at $20.08, down 5.1% today amid bearish technical signals. The stock shows extreme valuation metrics with P/S of 551.27 and negative profitability, though analyst consensus remains unanimously bullish with a $39.86 price target representing 99% upside. Recent IDC MarketScape recognition and government grants highlight technological progress, but substantial cash burn and negative margins pose fundamental challenges.
While analyst optimism and quantum computing's long-term potential offer speculative appeal, QBTS faces significant execution risks with negative earnings, high cash burn, and competitive threats. The stock's current technical weakness near key support at $20 suggests near-term pressure, making it suitable only for risk-tolerant investors betting on quantum commercialization timelines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
